

IDT CORP  
Form 8-K  
June 30, 2005

---

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

---

**FORM 8-K**

---

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): June 28, 2005**

---

**IDT CORPORATION**

(Exact name of registrant as specified in its charter)

---

**Delaware**  
(State or other jurisdiction

of incorporation)

**1-16371**  
(Commission File Number)

**22-3415036**  
(IRS Employer

Identification No.)

**520 Broad Street**

**Newark, New Jersey**  
(Address of principal executive offices)

**07102**  
(Zip Code)

Edgar Filing: IDT CORP - Form 8-K

Registrant's telephone number, including area code: (973) 438-1000

**Not Applicable**

(Former name or former address, if changed since last report.)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 8.01 Other Events.**

On June 28, 2005, the Registrant issued a press release, a copy of which is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.

**Item 9.01 EXHIBITS**

Exhibit 99.1 Press Release of the Registrant dated June 28, 2005.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**IDT CORPORATION**

Dated: June 29, 2005

By: \_\_\_\_\_ /s/ JAMES A. COURTER

\_\_\_\_\_  
**James A. Courter**  
*Chief Executive Officer*

---

**EXHIBIT INDEX**
**Exhibit**

<u>Number</u>	<u>Description</u>
99.1	Press Release of the Registrant dated June 28, 2005.
2	Item 5.07 Submission of Matters to a Vote of Security Holders.

(a) The Annual Meeting of the Company was held on May 23, 2012.

(b) The following proposals were submitted to the stockholders and voted upon at the Annual Meeting: (i) the election of three Class 3 director nominees to the Company's board of directors; (ii) the approval of an amendment to the Company's certificate of incorporation, by way of an Amended and Restated Certificate of Incorporation, to effectuate a reverse stock split of the Company's common stock at a ratio of up to and including one-for-ten, such ratio to be determined by the board of directors of the Company; (iii) the approval of an amendment to the Company's Amended and Restated 2006 Equity Incentive Plan to increase the number of shares available for the grant of awards by 4,800,000 shares (on a pre-split basis); and (iv) the ratification of the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2012.

Votes of the common stock stockholders regarding the election of the director nominees were as follows:

	Votes		Broker
	Votes For	Withheld	Non-Votes
Paul McBarron	12,227,478	8,481,152	22,968,160
Dr. Nicholas Bacopoulos	17,417,706	3,290,924	22,968,160
Dr. Christopher Henney	16,513,239	4,195,391	22,968,160

Based on the votes set forth above, Paul McBarron, Dr. Nicholas Bacopoulos and Dr. Christopher Henney were duly elected as Class 3 directors of the Company to serve until the 2015 annual meeting of stockholders or until their respective successors are elected and qualified or until their earlier resignation or removal.

Votes of the common stock stockholders regarding the amendment to the Company's certificate of incorporation, by way of an Amended and Restated Certificate of Incorporation, to effectuate a reverse stock split of the Company's common stock at a ratio of up to and including one-for-ten, such ratio to be determined by the board of directors of the Company, were as follows:

Edgar Filing: IDT CORP - Form 8-K

<b>Votes For</b>	<b>Votes Against</b>	<b>Abstentions</b>	<b>Broker Non-Votes</b>
31,786,557	11,669,687	220,546	

Based on the votes set forth above, the proposal to amend the Company's certificate of incorporation, by way of an Amended and Restated Certificate of Incorporation, to effectuate a reverse stock split of the Company's common stock at a ratio of up to and including one-for-ten, such ratio to be determined by the board of directors was approved. The board of directors of the Company, in its sole discretion, may resolve not to effect a reverse stock split.

Votes of the stockholders regarding the amendment to the Company's Amended and Restated 2006 Equity Incentive Plan to increase the number of shares available for the grant of awards by 4,800,000 shares (on a pre-split basis) were as follows:

<b>Votes For</b>	<b>Votes Against</b>	<b>Abstentions</b>	<b>Broker Non-Votes</b>
13,546,355	6,067,745	1,094,530	22,968,160

Based on the votes set forth above, the proposal to amend the Company's Amended and Restated 2006 Equity Incentive Plan to increase the number of shares available for the grant of awards under the plan by 4,800,000 shares (on a pre-split basis) was approved.

Further, the common stock stockholders of the Company ratified the election of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2012, with 41,504,996 votes for ratification, 1,856,813 votes against ratification, 314,981 abstentions and no broker non-votes.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits.

<b>Exhibit Number</b>	<b>Description</b>
10.1	Cyclacel Pharmaceuticals, Inc. Amended and Restated 2006 Equity Incentive Plan, as amended.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

**CYCLACEL PHARMACEUTICALS, INC.**

By:	/s/ Paul McBarron
Name:	Paul McBarron
Title:	Executive Vice President Finance, Chief Financial Officer and Chief Operating Officer

Date: May 24, 2012